Cohance Lifesciences accepts CFO Himanshu Agarwal resignation

Cohance Lifesciences Limited has accepted the resignation of Mr. Himanshu Agarwal from the positions of Whole-time Director and Chief Financial Officer (Key Managerial Personnel). His resignation is effective from the close of business hours on September 13, 2026. Agarwal is leaving the organisation to pursue a new professional opportunity outside the company.

The disclosure was made to the stock exchanges on June 17, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that there are no other material reasons for the resignation other than the career advancement opportunity cited by Agarwal.

Resignation Details

The transition follows a formal resignation email submitted by Agarwal to the Chairman of the Board of Directors & CEO. In his communication, Agarwal expressed gratitude to the Board and leadership team for their support during his tenure. He affirmed his commitment to ensuring an orderly handover of responsibilities and supporting the management in the onboarding of his successor before his departure.

The table below outlines the key regulatory disclosures regarding the change in the company's leadership:

Disclosure Requirement	Details
Reason for change	Resignation of Mr. Himanshu Agarwal (DIN-06672915), Whole-time Director and Chief Financial Officer (Key Managerial Personnel)
Date of cessation	Close of business hours on 13 September 2026
Brief profile	Not Applicable
Disclosure of relationships	Not Applicable

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.92%	-4.16%	-5.19%	-23.37%	-59.80%	-15.38%

Cohance Lifesciences Limited shareholders have approved the appointment of Mr. Umang Vohra as Chairman and Group Chief Executive Officer, effective May 1 and May 20, 2026, respectively. The postal ballot results, declared on June 14, 2026, also sanctioned the 'Cohance Lifesciences Limited – Employee Stock Option Plan, 2026' and the payment of remuneration to Mr. Vohra exceeding the limits prescribed under Section 197 of the Companies Act, 2013.

The remote e-voting process, conducted by KFin Technologies Limited, commenced on May 15, 2026, and concluded on June 13, 2026. Mr. DVM Gopal of M/s. DVM & Associates LLP served as the Scrutinizer for the process. The resolutions were passed with the required majority, though public institutions showed significant opposition to the remuneration and stock option grant proposals.

Voting Results Summary

The postal ballot sought approval for five special and ordinary resolutions. While the appointment of Mr. Vohra received overwhelming support, resolutions concerning remuneration and stock options faced notable dissent from public institutional shareholders.

Resolution	Votes For	Votes Against	% For	% Against
Appointment of Mr. Umang Vohra	340,783,692	1,304,180	99.62%	0.38%
Remuneration exceeding Section 197 limits	302,974,002	39,113,870	88.57%	11.43%
ESOP 2026	330,334,573	11,743,299	96.57%	3.43%
Extension of ESOP to unlisted subsidiaries	330,570,749	11,507,123	96.64%	3.36%
Grant of options >= 1% of issued capital	301,584,656	40,493,216	88.16%	11.84%

Key Approvals

The members approved the appointment of Mr. Umang Vohra (DIN: 02296740) as Chairman of the Company with effect from May 1, 2026, and as Group Chief Executive Officer with effect from May 20, 2026. Additionally, the 'Cohance Lifesciences Limited – Employee Stock Option Plan, 2026' was approved, along with its extension to unlisted subsidiary companies.

Shareholders also authorized the grant of stock options equal to or exceeding 1% of the issued capital of the Company in a single financial year. The record date for determining eligibility was May 8, 2026. The detailed scrutinizer's report has been made available on the company's website.